Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-009817
Filing Date
2024-07-15
Accepted
2024-07-15 16:15:29
Documents
38
Period of Report
2024-05-31

Document Format Files

Seq Description Document Type Size
1 10-Q bzyr-20240531x10q.htm   iXBRL 10-Q 469237
2 EX-31.1 bzyr-20240531xex31d1.htm EX-31.1 11664
3 EX-31.2 bzyr-20240531xex31d2.htm EX-31.2 11948
4 EX-32.1 bzyr-20240531xex32d1.htm EX-32.1 6686
5 EX-32.2 bzyr-20240531xex32d2.htm EX-32.2 7116
  Complete submission text file 0001558370-24-009817.txt   1899024

Data Files

Seq Description Document Type Size
6 EX-101.SCH bzyr-20240531.xsd EX-101.SCH 17063
7 EX-101.CAL bzyr-20240531_cal.xml EX-101.CAL 17612
8 EX-101.DEF bzyr-20240531_def.xml EX-101.DEF 43943
9 EX-101.LAB bzyr-20240531_lab.xml EX-101.LAB 136854
10 EX-101.PRE bzyr-20240531_pre.xml EX-101.PRE 90841
41 EXTRACTED XBRL INSTANCE DOCUMENT bzyr-20240531x10q_htm.xml XML 133051
Mailing Address 9432 KATY FREEWAY HOUSTON TX 77055
Business Address 12000 RICHMOND AVE HOUSTON TX 77082 (713) 335-5697
BURZYNSKI RESEARCH INSTITUTE INC (Filer) CIK: 0000724445 (see all company filings)

EIN.: 760136810 | State of Incorp.: DE | Fiscal Year End: 0229
Type: 10-Q | Act: 34 | File No.: 000-23425 | Film No.: 241117454
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)